Figure 5. Characterization of the agonistic antibody Htr-9.

a) SEC of purified Htr-9. b) ELISA analyzing binding of Htr-9 and ATROSAB to immobilized human and mouse TNFR1-Fc and TNFR2-Fc. c) Binding of Htr-9 to human TNFR1-Fc analyzed by QCM at a medium receptor density (indicated by a 48 Hz resonance frequency shift). Htr-9 was analyzed at concentrations between 1 µM–62.5 nM. d) Binding of ATROSAB and Htr-9 to immobilized human TNFR1-Fc in ELISA. e) Inhibition of binding of Htr-9 (7 nM) to human TNFR1-Fc by increasing concentrations of ATROSAB. f) Inhibition of binding of TNF (1 nM) to immobilized human TNFR1-Fc in ELISA by increasing concentrations of Htr-9 or ATROSAB, respectively.